DVTC Stock Overview
Pegasus Pharmaceuticals Inc. manufactures and provides an advanced ECG system for the non-invasive screening of heart pathologies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Development Technologies Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.94 |
| 52 Week High | US$17.55 |
| 52 Week Low | US$5.94 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -0.17% |
| 1 Year Change | n/a |
| 3 Year Change | -50.50% |
| 5 Year Change | 37.66% |
| Change since IPO | -99.87% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| DVTC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how DVTC performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how DVTC performed against the US Market.
Price Volatility
| DVTC volatility | |
|---|---|
| DVTC Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DVTC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DVTC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Daniel Kesonen | www.pegasusbiosciences.com |
Pegasus Pharmaceuticals Inc. manufactures and provides an advanced ECG system for the non-invasive screening of heart pathologies. The company offers HeartVue 6S System, which is a screening tool used to diagnose heart and other cardiac diseases. It serves cardiologists, general practitioners, physicians, intensive care units, hospitals, emergency rooms, clinics, fitness facilities, sports teams, and other emergency medical facilities.
Development Technologies Corp. Fundamentals Summary
| DVTC fundamental statistics | |
|---|---|
| Market cap | US$65.35m |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs DVTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DVTC perform over the long term?
See historical performance and comparison